Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Adverse events

From: A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)

  Grade Standard
(N = 16)
Experimental
(N = 14)
p value
Liver function abnormalities G I/II 9 (56.3%) 9 (64.3%) 0.72
Grade III/IV 0 (0.0%) 2 (14.3%) 0.21
Fatigue G I/II 8 (50.0%) 6 (42.9%) 0.73
Grade III/IV 0 (0.0%) 1 (7.1%) 0.47
Diarrhea G I/II 7 (43.8%) 7 (50.0%) 1.00
Neuropathy G I/II 3 (18.8%) 3 (21.4%) 1.00
Rash G I/II 3 (18.8%) 3 (21.4%) 1.00
Hypokalemia G I/II 5 (31.3%) 2 (14.3%) 0.40
Grade III/IV 1 (6.3%) 1 (7.1%) 1.00
Hypomagnesemia G I/II 1 (6.3%) 0 (0.0%) 1.00
Mucositis G I/II 1 (6.3%) 1 (7.1%) 1.00
Nail discoloration G I/II 0 (0.0%) 1 (7.1%) 0.47
Skin discoloration G I/II 0 (0.0%) 1 (7.1%) 0.47
Nausea G I/II 3 (18.8%) 0 (0.0%) 0.23
Constipation G I/II 0 (0.0%) 1 (7.1%) 0.47
Depression G I/II 1 (6.3%) 1 (7.1%) 1.00
Anxiety G I/II 1 (6.3%) 0 (0.0%) 1.00
Epistaxis G I/II 0 (0.0%) 2 (14.3%) 0.21
Chest pain G I/II 1 (6.3%) 0 (0.0%) 1.00
Myocardial infarction G I/II 0 (0.0% 0 (0.0%) 1.00
Grade III/IV/V 0 (0.0%) 1 (7.1%) 0.47
Musculoskeletal pain G I/II 1 (6.3%) 0 (0.0%) 1.00
Breast pain G I/II 1 (6.3%) 0 (0.0%) 1.00
Platelet count decreased G I/II 0 (0.0%) 1 (7.1%) 0.47
Neutrophil count decreased G I/II 0 (0.0%) 1 (7.1%) 0.47